Neuroma Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma
Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.
Subjects will have painful primary or post-operative intermetatarsal neuroma. Each subject
will be randomly allocated to receive either ALGRX 4975 or placebo in a 1:1 ratio. Study
drug or placebo will be injected into the intermetatarsal space containing a painful
neuroma. Subjects will complete weekly assessments for the Average Foot Pain Severity, the 7
Interference Items of the BPI, and the number of analgesic units taken. Some subjects may be
followed by monthly telephone interviews to assess their level of pain over the six-month
period following treatment.
Plasma concentrations will be assessed pre-dose and post dose at 5, 10, 15, 20, 30, and 45
min and at 1, 1.5, 2, 2.5, 3 and 4 hours.
Safety will be assessed at baseline and during the study with adverse events (all visits),
vital signs (Visit 2 pre and post-injection and Visit 3 or at early termination), and
laboratory assessments (hematology, chemistry, urinalysis) and ECG (Screening and Visit 3 or
at early termination). The injection site will be examined and assessed by a 6-point scale
for erythema, edema, and hemorrhage before the injection and at 1, 2 and 4 hours after the
injection. A pain on injection NRS will be assessed immediately post- injection at 15, 30,
and 45 minutes and 1, 2, 3, and 4 hours after study drug administration. A sensory
examination of the foot will be performed before the injection and 4 hours after the
injection and at the completion of the study. If a subject has injection pain, the foot may
be wrapped in ice for up to 20 minutes, analgesic medication may be provided.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Recruiting |
NCT05008185 -
Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation
|
||
Completed |
NCT02316262 -
Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation
|
N/A | |
Completed |
NCT02205385 -
Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation
|
N/A | |
Completed |
NCT04931056 -
A Post Market Clinical Follow-up Study on Biomet Microfixation HTR PEKK (Midface), Facial & Mandibular Plates.
|
||
Completed |
NCT01632709 -
Pathophysiology of Post Amputation Pain
|
Phase 4 | |
Completed |
NCT02528266 -
Surgical Treatment of Symptomatic Neuroma "Stop Neuroma"
|
N/A | |
Withdrawn |
NCT01374191 -
Botulinum Toxin Type A for Neuroma Pain
|
Phase 2 | |
Enrolling by invitation |
NCT06164392 -
Evaluation of Neuroma Perfusion With Indocyanine Green Fluorescence Angiography
|
Phase 4 | |
Completed |
NCT03484429 -
Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
|
N/A | |
Completed |
NCT03051113 -
Identification of Neuromas by High Resolution Ultrasound in Patients With Peripheral Nerve Injury and Amputations
|
||
Completed |
NCT02993276 -
Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma
|